Floatz logo

Nivolumab

Ocular Melanoma

University of Michigan Rogel Cancer Centermonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Ocular Melanoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
University of Michigan Rogel Cancer Center
Phase 2BB
BELZUPACAP SAROTALOCAN
Aura Biosciences
Phase 2BB
Polyiclc
Craig L Slingluff, Jr
Phase 2B
Aflibercept
Centre Hospitalier Universitaire de Nice
Phase 3B
Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B

View all 25 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →